Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
May 12, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
May 09, 2022 16:04 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
May 02, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
April 20, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
March 15, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 28, 2022 16:27 ET | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
February 28, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 25, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 22, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...